Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Aridis Pharmaceuticals Inc

Healthcare US ARDS

0.0002USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.00140.0014
LowHigh

52 Week Range

0.00010.0028
LowHigh

Fundamentals

  • Previous Close 0.0002
  • Market Cap0.00891M
  • Volume10
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.34700M
  • Revenue TTM22.36M
  • Revenue Per Share TTM0.69
  • Gross Profit TTM 5.21M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.37100M -43.19300M -22.33300M -29.68100M -22.10500M
Minority interest - - - - -
Net income -30.74900M -42.28100M -22.33300M -28.98600M -22.10500M
Selling general administrative 7.16M 7.31M 6.45M 6.03M 3.87M
Selling and marketing expenses - - - - -
Gross profit - 1.53M 1.00M 1.02M 2.76M
Reconciled depreciation 0.49M 0.43M 0.34M 0.34M 0.28M
Ebit -29.99300M -43.71100M -22.33300M -29.42500M -26.03200M
Ebitda -29.50600M -44.43300M 31.47M -29.08700M -25.74900M
Depreciation and amortization 0.49M -0.72200M 0.34M 0.34M 0.28M
Non operating income net other - - -0.00900M -0.59400M 2.01M
Operating income -29.99300M -43.71100M -22.40100M -29.08700M -24.11700M
Other operating expenses 29.99M 43.71M 23.40M 30.11M 26.87M
Interest expense 0.38M -0.24500M 0.00000M 0.00000M 0.42M
Tax provision - - - - -
Interest income - - 0.08M 0.59M 0.38M
Net interest income -0.12100M -0.24500M 0.08M 0.36M 0.42M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.38M -0.91200M -0.40500M -0.69500M 2.43M
Total revenue 0.00000M 1.53M 1.00M 1.02M 2.76M
Total operating expenses 29.99M 43.71M 23.40M 30.11M 26.87M
Cost of revenue - - - - 23.00M
Total other income expense net -0.37800M 0.52M 22.38M -0.59400M 1.59M
Discontinued operations - - - - -
Net income from continuing ops -30.37100M -43.19300M -22.33300M -29.68100M -22.10500M
Net income applicable to common shares - -46.32000M -22.33300M -29.68100M -23.46200M
Preferred stock and other adjustments - - - - 1.36M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14.70M 26.80M 15.12M 27.97M 31.61M
Intangible assets 0.02M 0.02M 0.03M 0.03M 0.04M
Earning assets - - - - -
Other current assets 5.51M 6.81M 6.88M 7.07M 2.45M
Total liab 38.93M 40.91M 23.80M 24.33M 5.30M
Total stockholder equity -24.23200M -14.11000M -8.68100M 3.64M 26.31M
Deferred long term liab - 0.10M 0.09M 0.53M -
Other current liab 9.58M 6.57M 1.37M 2.97M 0.46M
Common stock 0.00300M 0.00200M 0.00100M 0.00100M 0.00100M
Capital stock 0.00300M 0.00200M 0.00100M 0.00100M 0.00100M
Retained earnings -195.66600M -165.29500M -123.10200M -100.76900M -71.08800M
Other liab - 1.28M 1.36M 5.00M -
Good will - - - - -
Other assets - -2.31000M -2.27200M -1.60400M 0.99M
Cash 4.88M 19.99M 8.23M 20.90M 24.24M
Cash and equivalents - - - - -
Total current liabilities 36.90M 33.35M 22.44M 19.33M 5.30M
Current deferred revenue 20.17M 20.84M 18.75M 14.60M 0.02M
Net debt 1.25M -14.00800M -7.51700M -20.89700M -24.23700M
Short term debt 4.84M 0.70M 0.44M - 2.49M
Short long term debt 4.30M 0.70M 0.44M - -
Short long term debt total 6.13M 5.98M 0.71M - -
Other stockholder equity 166.38M 151.18M 114.42M 104.40M 66.28M
Property plant equipment - 1.36M 1.26M 1.01M 1.27M
Total current assets 11.63M 26.80M 15.12M 27.97M 24.24M
Long term investments - - - 0.00900M 0.96M
Net tangible assets - -13.13200M -8.70800M 3.60M 26.28M
Short term investments - - - - -
Net receivables 1.24M 0.24M 0.37M 0.41M 1.66M
Long term debt - 5.28M 0.28M - -
Inventory - -0.23700M -0.36800M -0.41300M -4.11000M
Accounts payable 2.31M 5.24M 1.89M 1.75M 2.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.05M - - -0.82300M -0.49100M
Additional paid in capital - - - - -
Common stock total equity - - 0.00100M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - -123.10200M -100.76900M -71.08800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.91M -1.37900M -1.28500M -1.04700M 7.37M
Deferred long term asset charges - - - - -
Non current assets total 3.07M 2.31M 2.27M 1.60M 7.37M
Capital lease obligations 1.83M - - - -
Long term debt total - - 0.28M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.08200M -0.53000M -0.36700M -0.17400M -1.00000M
Change to liabilities - 4.80M -0.08300M -0.47100M 2.10M
Total cashflows from investing activities - -0.53000M -0.36700M -0.17400M -1.67700M
Net borrowings - 5.00M 0.71M 0.71M 0.71M
Total cash from financing activities 14.78M 34.72M 8.68M 4.99M 25.09M
Change to operating activities - 5.58M -0.53400M -2.54800M -2.05500M
Net income -30.37100M -42.19300M -22.33300M -29.68100M -22.10500M
Change in cash -14.42700M 11.25M -12.16500M -3.34000M -0.85900M
Begin period cash flow 19.99M 8.73M 20.90M 24.24M 25.10M
End period cash flow 5.56M 19.99M 8.73M 20.90M 24.24M
Total cash from operating activities -29.12700M -22.93600M -20.47600M -8.15900M -24.27100M
Issuance of capital stock 12.61M 29.71M 7.95M 4.96M 25.08M
Depreciation 0.49M 0.43M 0.34M 0.34M 0.28M
Other cashflows from investing activities - - - - -1.00000M
Dividends paid - -4.12700M - - 1.36M
Change to inventory - - - -2.54800M -2.85500M
Change to account receivables -1.00000M 0.13M -0.14400M 1.66M -1.66000M
Sale purchase of stock - - 7.96M 4.99M 25.09M
Other cashflows from financing activities 3.97M 9.13M 0.73M 0.04M 1.37M
Change to netincome - 8.05M 2.14M 2.01M 0.03M
Capital expenditures 0.08M 0.53M 0.37M 0.17M 0.68M
Change receivables - - -0.14400M 1.69M -1.66000M
Cash flows other operating - - 0.37M 17.96M -2.91200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -12.16500M -3.34000M -0.85900M
Change in working capital -1.29900M 10.52M -0.61700M 18.22M -2.51500M
Stock based compensation 1.48M 2.25M 2.13M 2.01M 1.66M
Other non cash items 0.58M 6.78M 0.00900M 0.95M -1.59200M
Free cash flow -29.20900M -23.46600M -20.84300M -8.33300M -24.94800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARDS
Aridis Pharmaceuticals Inc		 - -% 0.0002 - 2.06 0.0004 5.40 0.25 -0.8707
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Aridis Pharmaceuticals Inc

983 University Avenue, Los Gatos, CA, United States, 95032

Key Executives

Name Title Year Born
Dr. Vu L. Truong Ph.D. Founder, CEO, Chief Scientific Officer & Director 1964
Mr. Fred Kurland J.D., M.B.A. Chief Financial Officer 1951
Dr. Hasan Jafri M.D. Chief Medical Officer NA
Mr. Jeffrey J. Fessler Esq., J.D. Acting Gen. Counsel 1963
Dr. Eric J. Patzer Ph.D. Founder & Executive Chairman 1949
Dr. Hasan Jafri M.D. Chief Medical Officer 1967
Ms. Tamara S. Allen Vice President of Finance 1967
Mr. Jeffrey J. Fessler Esq., J.D. Acting General Counsel 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.